LIR

Lir Biopharma is a clinical-stage biotechnology company focused on developing innovative therapies for metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Founded in 2020 by Dr. Jin-Long Chen, the former CSO of NGM Biopharmaceuticals, the company leverages its expertise in peptide and protein engineering to create next-generation multi-agonist treatments. Its lead candidate, LR004, is a triple agonist targeting the GLP-1, GIP, and glucagon receptors, currently undergoing Phase 2 clinical trials to provide superior weight loss and glycemic control. Lir Biopharma aims to differentiate its pipeline by optimizing the balance of receptor activation to enhance efficacy and tolerability. The company is headquartered in Suzhou, China, and is backed by prominent venture capital firms including Matrix Partners China and Qiming Venture Partners.